v3.25.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS (Tables)
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of allocated to the underlying assets acquired and liabilities assumed
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values including insignificant measurement period adjustments as follows:
(In thousands)
Net operating assets$14,643 
Developed technology26,000 
Total identifiable assets acquired40,643 
Net operating liabilities(7,357)
Net identifiable assets acquired33,286 
Goodwill20,916 
Net assets acquired$54,202 
Schedule of business acquisitions, by acquisition Stock issuances in relation to acquisitions during the years ended December 31, 2024, 2023, and 2022 were as follows:
(In thousands, except for per share data)
Period of AcquisitionShares IssuedFair Value of Shares Issued
OmicEraMay 2022265,186$14,792 
The acquisition date fair value of the consideration transferred for Resolution Bioscience was approximately $54.2 million, which consisted of the following:
(In thousands)
Cash$52,527 
Fair value of replaced equity awards1,675 
Total purchase price$54,202 
The acquisition date fair value of the consideration transferred for OmicEra was approximately $19.4 million, which consisted of the following:
(In thousands)
Common stock issued$14,792 
Contingent consideration4,600 
Cash paid related to working capital adjustment16 
Total purchase price$19,408 
Schedule of Noncash or Part Noncash Divestitures
The closing date fair value of the consideration received for the asset was approximately $29.6 million, which consisted of the following:
(In thousands)
Cash$25,000 
MDxHealth American Depository Shares 4,631 
Contingent consideration— 
Total consideration$29,631 
Business combination, pro forma information
The following unaudited pro forma financial information summarizes the combined results of operations for the Company and Resolution Bioscience, as though the companies were combined as of the beginning of January 1, 2022.
Twelve Months Ended December 31,
(In thousands)20232022
Total revenues$2,507,111 $2,097,680 
Net loss before tax(237,854)(675,091)